Jci_page_head_homepage_01 Jci_page_head_homepage_02
Jeffrey E. Galvin, Mark E. Hemric, Kent Ward, Madeleine W. Cunningham
Published in Volume 106, Issue 2
J Clin Invest. 2000; 106(2):217–224 doi:10.1172/JCI7132
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 3

(a) Dose-response curve of mAb 3.B6 reacted with HCM, HCM subfragments (HMM and S1), GlcNAc-BSA, and BSA by ELISA. Although mAb 3.B6 reacted with HCM, HMM, and GlcNAc, the strongest reactivity was with the S1 subfragment. (b) Reactivity of mAb 3.B6 with human LMM peptides in the immunodot blot assay. Fifty micrograms of peptide were adsorbed onto nitrocellulose and reacted with mAb 3.B6 (10 μg/mL); mAb 3.B6 binding was detected by peroxidase-conjugated anti-human IgM antibodies. Samples were performed in duplicate. PBS was the negative control in which no peptide was blotted onto nitrocellulose. Monoclonal antibody 3.B6 reacted with LMM 1, LMM 33, and weakly with LMM 17, as shown.